PN20
Phase 1Small molecule
PN20 is one of 74 small molecule programs targeting Thrombocytopenia. It is currently in Phase 1.
2
Indications
4
Total Trials
2
Active Trials
73
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
135 competitors in Immune Thrombocytopenia
#DrugCompanyPhaseTrials
1Nplate
AmgenPhase 3
Rysodeg
UCBPhase 3
Cellcept
RochePhase 3
Vyvgart
ArgenxPhase 3
Doptelet
AAkarx
Phase 3
Fabhalta
Johnson & JohnsonPhase 3
Wayrilz
GGenzyme, a Sanofi Company
Phase 3
Nublexa
BBeijing InnoCare Pharma Tech Co., Ltd.
Phase 3
Tamiflu
CConrado Roberto Hoffmann Filho
Phase 3
Avlosulfon
AAlmirall, S.A.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for PN20. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details